ProShares Ultra Nasdaq Biotechnology Rating $42.21 -0.34 (-0.80%) Closing price 03:59 PM EasternExtended Trading$42.22 +0.02 (+0.04%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock ProShares Ultra Nasdaq Biotechnology Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BIB Aggregate RatingModerate Buy 2.72Holdings in BIB have an aggregate rating of Moderate Buy based on 689 analyst ratings issued in the past year covering 44 companies (62.0% of the portfolio).BIB Aggregate Price Target$42.21High Prediction$42.21Average Prediction$42.21Low Prediction$42.21Holdings in BIB have an aggregate price target of $42.21 and a range of $42.21 to $42.21 covering 44 companies (62.0% of the portfolio).BIB Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy14 Buy rating(s)Moderate Buy23 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ProShares Ultra Nasdaq Biotechnology Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 44 BIB Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.88%VRTXVertex Pharmaceuticals$500.49+0.9%4.0986 of 5 stars2.64$512.41 2.4%25Short Interest ↓Analyst RevisionPositive News6.78%AMGNAmgen$295.30+0.5%4.2687 of 5 stars2.48$314.91 6.6%23Analyst ForecastNews Coverage6.68%GILDGilead Sciences$105.68-0.8%4.5363 of 5 stars2.72$105.12 -0.5%29Positive News5.73%REGNRegeneron Pharmaceuticals$557.91-2.3%4.8718 of 5 stars2.77$964.88 72.9%26Analyst ForecastPositive News3.58%AZNAstraZeneca$67.87-0.2%3.3388 of 5 stars3.09$86.80 27.9%11Analyst ForecastShort Interest ↓Analyst Revision2.94%ALNYAlnylam Pharmaceuticals$230.93-3.8%4.507 of 5 stars2.77$315.58 36.7%261.64%BIIBBiogen$116.98-1.9%4.6943 of 5 stars2.42$213.15 82.2%31Analyst Revision1.59%ARGXargenx$605.38-0.2%3.2573 of 5 stars2.91$690.33 14.0%231.32%SNYSanofi$50.60-2.4%4.2359 of 5 stars3.00$63.33 25.2%6Analyst ForecastShort Interest ↓Positive NewsHigh Trading Volume1.29%SMMTSummit Therapeutics$24.62-5.8%2.6284 of 5 stars3.00$35.40 43.8%10News Coverage1.19%UTHRUnited Therapeutics$284.82+0.2%4.9019 of 5 stars2.67$388.25 36.3%12Insider TradeNews CoveragePositive NewsGap Down1.15%RPRXRoyalty Pharma$32.45+0.5%4.5171 of 5 stars3.00$42.50 31.0%5Positive News1.13%INSMInsmed$71.07+0.1%4.1144 of 5 stars3.00$94.00 32.3%16Positive News1.11%BMRNBioMarin Pharmaceutical$60.02+0.6%4.887 of 5 stars2.71$94.00 56.6%24Positive News1.10%ILMNIllumina$74.59-0.6%4.653 of 5 stars2.48$138.70 85.9%21News Coverage1.03%INCYIncyte$58.46-1.3%4.8624 of 5 stars2.21$74.88 28.1%190.98%ONCBeigene$238.84-1.6%2.2987 of 5 stars3.00$316.67 32.6%3Gap Down0.92%NBIXNeurocrine Biosciences$96.16+1.3%4.8388 of 5 stars2.91$161.86 68.3%23Analyst UpgradeNews CoveragePositive NewsGap Up0.91%MRNAModerna$26.24-2.1%4.3298 of 5 stars2.04$58.70 123.7%24Gap Down0.88%VTRSViatris$7.48-2.0%2.963 of 5 stars1.75$10.50 40.4%4News Coverage0.88%EXELExelixis$36.54+2.2%4.2548 of 5 stars2.50$37.59 2.9%20Positive NewsGap Down0.81%MEDPMedpace$305.00-0.1%4.434 of 5 stars2.31$357.50 17.2%13Upcoming EarningsAnalyst DowngradeNews Coverage0.79%BNTXBioNTech$99.00-3.3%2.695 of 5 stars2.89$143.44 44.9%18Positive News0.78%ASNDAscendis Pharma A/S$153.92-1.0%2.3124 of 5 stars2.93$204.64 33.0%14News CoveragePositive NewsGap Down0.71%TEMTempus AI$42.93-0.5%2.4323 of 5 stars2.50$61.18 42.5%12Gap Down0.66%HALOHalozyme Therapeutics$61.28-0.2%4.3932 of 5 stars2.60$62.78 2.4%10Positive News0.65%JAZZJazz Pharmaceuticals$102.91+1.1%4.8839 of 5 stars2.93$187.71 82.4%14Positive NewsGap Down0.63%MDGLMadrigal Pharmaceuticals$321.10-0.4%4.0481 of 5 stars2.80$378.44 17.9%10News CoveragePositive News0.61%ROIVRoivant Sciences$10.06-1.3%2.6217 of 5 stars3.00$17.50 74.0%4Positive News0.56%BBIOBridgeBio Pharma$34.24-1.8%4.5723 of 5 stars2.92$53.00 54.8%12Analyst ForecastPositive News0.55%RVMDRevolution Medicines$36.32-0.4%3.816 of 5 stars3.00$66.67 83.6%12Positive News0.52%SRPTSarepta Therapeutics$54.42-0.4%4.6743 of 5 stars2.83$161.83 197.4%24Short Interest ↑0.49%BPMCBlueprint Medicines$81.45-1.3%2.6248 of 5 stars2.70$124.95 53.4%23Positive News0.46%GHGuardant Health$44.85-0.7%3.6829 of 5 stars3.05$49.00 9.3%210.46%AXSMAxsome Therapeutics$103.83+0.3%4.5244 of 5 stars3.00$169.80 63.5%16Analyst Revision0.45%ALKSAlkermes$27.94+1.5%4.7281 of 5 stars2.67$38.50 37.8%12Short Interest ↓Analyst RevisionPositive News0.44%KRYSKrystal Biotech$169.13+0.1%4.6457 of 5 stars3.00$220.00 30.1%80.41%CYTKCytokinetics$38.56-3.1%3.7824 of 5 stars2.94$81.63 111.7%18Analyst ForecastGap Down0.41%ADMAADMA Biologics$22.15+5.9%1.8772 of 5 stars3.25$22.50 1.6%4Options VolumeNews CoveragePositive NewsGap Up0.40%VRNAVerona Pharma$58.47+1.1%2.2607 of 5 stars3.14$69.14 18.3%7Positive NewsGap Down0.40%NUVLNuvalent$70.78+1.1%1.9881 of 5 stars2.91$113.44 60.3%11Positive News0.39%IONSIonis Pharmaceuticals$28.38-1.0%4.0557 of 5 stars2.70$56.72 99.9%20Analyst Forecast0.37%PCVXVaxcyte$30.23-5.6%3.2561 of 5 stars3.10$136.50 351.5%10Positive NewsHigh Trading Volume0.32%PTCTPTC Therapeutics$46.94+4.1%3.8871 of 5 stars2.53$63.77 35.9%15Short Interest ↑Positive News This page (NASDAQ:BIB) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares Ultra Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares Ultra Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BIB Stock Free BIB Stock Alerts